Rapastinel Catalog No.:M13065-2 PD173074 treatment potently reduces viability

PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM

which is currently under clinical trial for Alzheimer's disease

Drug therapy

InChi: InChI=1S/C19H35N3O5/c1-4-5-6-8-14(11-16(24)21-27)18(25)20-17(13(2)3)19(26)22-10-7-9-15(22)12-23/h13-15

InChi: InChI=1S/C122H196N40O39/c1-55(2)40-76(141-63(13)169)99(181)138-50-91(176)142-69(18-14-36-135-120(128)129)100(182)150-79(43-58(7)8)108(190)157-85(53-164)113(195)147-72(30-33-87(123)172)102(184)145-74(32-35-93(178)179)103(185)152-78(42-57(5)6)107(189)153-80(46-66-49-134-54-140-66)109(191)144-70(19-15-37-136-121(130)131)101(183)151-77(41-56(3)4)106(188)146-73(31-34-88(124)173)105(187)160-97(62(12)168)118(200)156-83(45-65-24-28-68(171)29-25-65)119(201)162-39-17-21-86(162)114(196)148-71(20-16-38-137-122(132)133)104(186)159-96(61(11)167)117(199)155-82(48-90(126)175)111(193)158-94(59(9)165)115(197)139-51-92(177)143-84(52-163)112(194)154-81(47-89(125)174)110(192)161-95(60(10)166)116(198)149-75(98(127)180)44-64-22-26-67(170)27-23-64/h22-29

Rapastinel Catalog No.:M13065-2 PD173074 treatment potently reduces viabilityRapastinel (GLYX 13) is an N methyl D aspartate receptor (NMDAR) modulator that has characteristics of a glycine site partial agonist. Target: NMDA Rapastinel is a robust cognitive enhancer and facilitates hippocampal long term potentiation (LTP) of synaptic transmission in slices. Product information CAS Number: 117928 94 6 Molecular Weight: 413. 47 Formula: C18H31N5O6 Synonym: GLYX 13 Chemical Name: (2S,3R) 2 {[(2S) 1 [(2S) 1 [(2S,3R) 2 amino 3